| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Defining the critical hurdles in cancer immunotherapy.
|
J Transl Med
|
2011
|
2.32
|
|
2
|
Cytomegalovirus infection: a driving force in human T cell immunosenescence.
|
Ann N Y Acad Sci
|
2007
|
1.87
|
|
3
|
Harmonization of immune biomarker assays for clinical studies.
|
Sci Transl Med
|
2011
|
1.84
|
|
4
|
More than just tumor destruction: immunomodulation by thermal ablation of cancer.
|
Clin Dev Immunol
|
2011
|
1.56
|
|
5
|
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples.
|
PLoS Comput Biol
|
2013
|
1.35
|
|
6
|
Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
|
Cancer Res
|
2002
|
1.28
|
|
7
|
Towards patient-specific tumor antigen selection for vaccination.
|
Immunol Rev
|
2002
|
1.22
|
|
8
|
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
|
Prostate
|
2009
|
1.20
|
|
9
|
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
|
Cancer Res
|
2009
|
1.19
|
|
10
|
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
|
Clin Cancer Res
|
2013
|
1.05
|
|
11
|
Harmonization of the intracellular cytokine staining assay.
|
Cancer Immunol Immunother
|
2012
|
1.05
|
|
12
|
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
|
Clin Cancer Res
|
2006
|
1.02
|
|
13
|
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
|
Int J Cancer
|
2011
|
1.00
|
|
14
|
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
|
World J Urol
|
2013
|
0.98
|
|
15
|
High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors.
|
Eur J Immunol
|
2005
|
0.98
|
|
16
|
Modeling flow cytometry data for cancer vaccine immune monitoring.
|
Cancer Immunol Immunother
|
2010
|
0.98
|
|
17
|
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.
|
Cancer Immunol Immunother
|
2012
|
0.98
|
|
18
|
Human platelets express heat shock protein receptors and regulate dendritic cell maturation.
|
Blood
|
2002
|
0.96
|
|
19
|
T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence?
|
Aging Clin Exp Res
|
2006
|
0.94
|
|
20
|
Immunorejuvenation in the elderly.
|
Rejuvenation Res
|
2006
|
0.91
|
|
21
|
Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs.
|
Exp Hematol
|
2008
|
0.88
|
|
22
|
CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
|
Cancer Immunol Immunother
|
2004
|
0.87
|
|
23
|
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.
|
Cancer Immunol Immunother
|
2012
|
0.86
|
|
24
|
Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation.
|
Int J Cancer
|
2010
|
0.86
|
|
25
|
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
|
Cancer Immunol Immunother
|
2013
|
0.82
|
|
26
|
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.
|
Cytometry A
|
2014
|
0.81
|
|
27
|
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain.
|
Cancer Immunol Immunother
|
2007
|
0.81
|
|
28
|
Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.
|
Oncoimmunology
|
2013
|
0.81
|
|
29
|
Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation.
|
Cell Stress Chaperones
|
2011
|
0.80
|
|
30
|
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
|
Cancer Immunol Immunother
|
2015
|
0.77
|
|
31
|
A vaccine in renal cell carcinoma: are we nearing reality?
|
Expert Rev Anticancer Ther
|
2012
|
0.76
|
|
32
|
Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12-14, 2007 in Würzburg, Germany.
|
Cancer Immunol Immunother
|
2007
|
0.75
|
|
33
|
CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany.
|
Cancer Immunol Immunother
|
2009
|
0.75
|
|
34
|
CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.
|
Cancer Immunol Immunother
|
2010
|
0.75
|
|
35
|
Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunity.
|
Cancer Immunol Res
|
2013
|
0.75
|